Home

This is a temporarily open system that will be closed on May 20, 2025, and all review processes will follow the previous review standards (https://www.benthamscience.com), during the peer review process, strict adherence to peer review standards will be followed, and once accepted, the manuscript will be submitted to KeAi Publishing House for publication (The journal homepage is under construction).

Articles Processing Charges

To provide open access, this journal has an open access fee (also known as an Article Processing Charge, APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution.  The open access publication fee for this journal is USD2300 from 01-03-2024, plus taxes. 

Articles Processing Charges (APC) only become due after an article has been both reviewed and accepted for publication.  Therefore, submission of an article is not a guarantee that it will be published.  The final decision on the manuscript is made by the Editor-in-Chief on the basis of at least two independent peer-review reports.

Manuscript submission system is currently being upgraded. The new system will be Elsevier's EM system, which is scheduled to be officially launched on March 18, 2025. Until then, the OJS submission system will be used temporarily, and manuscripts submitted through this system will undergo double-blind peer review, just like formally submitted manuscripts.

Current Radiopharmaceuticals is one of the pharmaceutical series journals under KeAi Publishing, which is responsible for our journal's publication. Our journal will use the Elsevier's Editorial Manager (EM) submission system, but during the set up of the EM system, the Open Journal Systems (OJS) system is temporarily being used for submissions.

Elsevier publishes over 2,500 digital journals, includingThe LancetandCell, as well as 39,000 e-books and many iconic reference works. KeAi Publishing currently has more than 200 journals, and it was jointly established by two world's leading STM publishers—China Science Publishing & Media and Elsevier. It is a unique joint venture in the international publishing industry. KeAi Publishing, based in Beijing, publishes first-class research results that benefit global society. The official website of KeAi Publishing ishttps://www.keaipublishing.com/en/.

It should be noted that manuscripts submitted to this system will be published in an open access manner.

About the submission system: This is a temporary submission system. During the set up of the new system

Once Elsevier successfully builds the EM system for our journal, all manuscripts submitted during this period will be transferred to Elsevier's EM system and published by KeAi Publishing.

Current Radiopharmaceuticals publishes original research articles, letters, full-length/mini-reviews, drug clinical trial studies, and guest-edited issues on all aspects of research and development of radiation medicine & nuclear medicine & radiological imaging & computerized medical imaging and graphics & radiolabelled compound preparations,covering studies related to nuclear medicine, molecular imaging, radiotherapy, neuroradiology, interventional radiology, Radiooncology and radiobiology，investigative radiology, oncology, and basic research. The scope of the journal also covers the following areas, namely radio imaging techniques, computerized medical images and graphics, magnetic resonance Imaging (MRI), computed tomography (CT),preparation and application of radionuclide compounds, and their diagnostic, investigative, and therapeutic use, including the incorporation of tracer methods used in scientific research and applications. Articles related to the resources on radiation research in the field of biology and biophysics are also included.

This journal contains four sections:

Section A：Radiation medicine & Radiological imaging：This part mainly focuses on radiotherapy, radiobiology, radiation protection, dosimetry, radionuclide therapy, new medical imaging technology, AI image analysis, image genomics, multi-modal image fusion and other related research.This part of the research also covers the function and mechanism of ionizing radiation on organisms, the diagnosis, treatment and protection of radiation injury and its clinical transformation application, mainly including medical physics, radiochemistry, radiobiology, biophysics, radiation hematology, radiation immunology, radiogenetics, radiotoxicology, radiation dosimetry, radiation epidemiology, radiation injury clinic, radiotherapy, radioprotective drugs and sensitizing drugs, as well as the clinical transformation application of ionizing radiation, including clinical tumor radiotherapy. This part also includes neuroradiology, interventional radiology, radiotherapy, endoscopy, investigation radiology, molecular imaging, radiological imaging technology, magnetic resonance imaging (MRI), computed tomography (CT), PET/CT, DR,angiography, digital subtraction, fluoroscopy, X-ray and so on.

Section B: Nuclear medicine: Nuclear medicine is the product of combining modern science and technology such as nuclear technology, electronic technology, computer technology, chemistry, physics and biology with medicine. Including imaging and functional diagnosis, labeled immunoassays and clinical medicine, radionuclide therapy, nuclear medicine and tumor radiotherapy, tumor hyperthermia, oncology and basic research. It mainly focuses on nuclear medical imaging (PET, SPECT, PET-CT/MRI), molecular imaging (radioactive tracer, biomarker), radiopharmaceuticals development (radionuclide therapy), the application of nuclear medicine in cancer, neurological and cardiovascular diseases, thyroid diseases and internal irradiation treatment, and the application of AI in nuclear medical imaging analysis.

Section C: Radiopharmaceuticals and chemistry：This part pays attention to the development, synthesis, bioavailability, pharmacokinetics and clinical application of radionuclide compounds, the in-depth exploration of the application of radiopharmaceuticals and nuclear chemical materials in diagnosis and treatment, and the attention to the frontier research in the cross field of radiopharmaceuticals and molecular imaging. It not only covers the production of radionuclides, the synthesis and labeling of radiopharmaceuticals, and the quality control of radiopharmaceuticals, but also involves the application of radiopharmaceuticals in tumors, cardiovascular diseases, neuroscience, endocrinology, orthopedics, liver, gallbladder and gallbladder. In addition, we also pay attention to the role of nuclear chemistry in environmental monitoring, industrial testing and safety protection, and the expanded application of nuclear chemistry technology in non-medical fields. Comprises a preparation method of isotopes; Isotope separation and analysis technology; Isotope coordination (labeling) chemistry; Behavioral chemistry of isotopes, including technical research in environment, biology, plants, soil and extreme conditions; Metrology and standards of isotopes, and theoretical simulation; Research and application of medical nuclides in basic medicine and clinical medicine.

Section D: Computerized medical imaging and graphics & AI: This part relates to digital algorithmic advances, development, and application of digital imaging and AI in disease detection, diagnosis, intervention, prevention, precision medicine, and population health.  Included in the journal will be articles on novel computerized imaging or visualization techniques, including artificial intelligence and machine learning, augmented reality for surgical planning and guidance, big biomedical data visualization, computer-aided diagnosis, computerized-robotic surgery, image-guided therapy, imaging scanning and reconstruction, mobile and tele-imaging, radiomics, and imaging integration and modeling with other information relevant to digital health. The types of biomedical imaging include: magnetic resonance, computed tomography, ultrasound, ultrasonic electrocardiogram, electroencephalograph, nuclear medicine, X-ray, microwave, optical and multi-photon microscopy, video and sensory imaging, and the convergence of biomedical images with other non-imaging datasets.